Resources from the same session
723O - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)
Presenter: Jaume Capdevila Castillon
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA53 - Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
Presenter: Jennifer Chan
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 723O and LBA53
Presenter: Marianne Pavel
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Webcast
LBA54 - Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network
Presenter: Thomas Walter
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1182O - Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors
Presenter: Louis de Mestier du Bourg
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
724O - EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
Presenter: Eric Baudin
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA54, 1182O and 724O
Presenter: Nicola Fazio
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Slides
Webcast